Clearbridge explains that it has adopted an asset-light approach by partnering exclusively with a locally licensed and AABB-accredited biobank in Hong Kong, a strategic move to enable immediate revenue generating business and saving lead time than establishing its own
greenfield laboratory facility.
Catalist-listed Clearbridge Health has launched its adult immune cell banking business, targeting Southeast Asia and Hong Kong as primary markets.
The business is operated through Clearbridge’s wholly-owned subsidiary Cell Entrust Bio Co, based in Hong Kong. The cell banking service enables individuals to collect and store their own peripheral blood mononuclear cells (PBMCs) for future treatments such as cellular therapies for cancer and other conditions.
